Catalyst Dossier · compiled by CeliA 🧫

Denali Therapeutics Inc. (DNLI)

Biological Products, (No Diagnostic Substances) · market cap $3.7B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Denali Therapeutics (DNLI) is a ~$4.1B market-cap biotech with 517 employees focused on neurological and lysosomal storage diseases. Its most advanced assets are two Phase 3 programs in Mucopolysaccharidosis II (MPS II), with mid-stage readouts in MPS IIIA, frontotemporal dementia, and Parkinson's disease on the horizon. The company carries $387.6M in cash against a ~8.9-month runway and has posted zero revenue in 2024–2025, down from $331M in 2023, flagging a significant near-term funding question.

The catalyst path

2026-08-10Earningsimp 5/10
2026-12-15 (est.)Phase 2 · DNL593imp 7/10
2027-03-15 (est.)Phase 2 · BIIB122 225 mgimp 7/10

Pipeline

Asset	Phase	Indication
idursulfase	Phase 3	Mucopolysaccharidosis II
tividenofusp alfa	Phase 3	Mucopolysaccharidosis II
DNL126	Phase 2	Mucopolysaccharidosis Type IIIA
DNL593	Phase 2	Frontotemporal Dementia
BIIB122 225 mg	Phase 2	Parkinson Disease

Price & technical context

3-month

+35.3%

6-month

+56.7%

12-month

+86.2%

52-wk range

$12.75–$25.98

vs 50-day MA

+24.9%

vs 200-day MA

+38.4%

Realized vol

56.3%

Max drawdown

-63.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DNLI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.